专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2012036810A8 THERMOPHILIC MUTANTS OF TRICHODERMA REESEI ENDOGLUCANASE I 审中-公开
标题翻译： TRICHODERMA REESEI内切葡聚糖I的热致突变体
公开(公告)号：WO2012036810A8
公开(公告)日：2013-05-30
申请号：PCT/US2011047361
申请日：2011-08-11
申请人： UNIV CALIFORNIA , CHOKHAWALA HARSHAL AKSHAY , KIM TAE-WAN , BLANCH HARVEY W , CLARK DOUGLAS S
发明人： CHOKHAWALA HARSHAL AKSHAY , KIM TAE-WAN , BLANCH HARVEY W , CLARK DOUGLAS S
IPC分类号： C12N9/42 , C12P21/06
CPC分类号： C12N9/2437 , C12N9/244 , C12P7/10 , C12P19/14 , C12P2201/00 , C12Y302/01004 , C12Y302/01006 , Y02E50/16
摘要： The present disclosure relates to mutant thermostable glycosyl hydrolases family 7 enzymes, including mutant Trichoderma reesei endoglucanase I. In particular, the present disclosure relates to mutant thermostable enzymes, compositions containing the enzymes, and methods of use thereof.
摘要翻译：本公开涉及突变型热稳定糖基水解酶家族7酶，包括突变型里氏木霉内切葡聚糖酶I.特别地，本公开涉及突变热稳定酶，含有酶的组合物及其使用方法。

2. 发明申请

WO2012036810A3 THERMOPHILIC MUTANTS OF TRICHODERMA REESEI ENDOGLUCANASE I 审中-公开
标题翻译： TRICHODERMA REESEI内切葡聚糖I的热致突变体
公开(公告)号：WO2012036810A3
公开(公告)日：2012-07-05
申请号：PCT/US2011047361
申请日：2011-08-11
申请人： UNIV CALIFORNIA , CHOKHAWALA HARSHAI AKSHAY , KIM TAE-WAN , BLANCH HARVEY W , CLARK DOUGLAS S
发明人： CHOKHAWALA HARSHAI AKSHAY , KIM TAE-WAN , BLANCH HARVEY W , CLARK DOUGLAS S
IPC分类号： C12N9/42 , C12P21/06
CPC分类号： C12N9/2437 , C12N9/244 , C12P7/10 , C12P19/14 , C12P2201/00 , C12Y302/01004 , C12Y302/01006 , Y02E50/16
摘要： The present disclosure relates to mutant thermostable glycosyl hydrolases family 7 enzymes, including mutant Trichoderma reesei endoglucanase I. In particular, the present disclosure relates to mutant thermostable enzymes, compositions containing the enzymes, and methods of use thereof.
摘要翻译：本公开涉及突变型热稳定糖基水解酶家族7酶，包括突变型里氏木霉内切葡聚糖酶I.特别地，本公开涉及突变热稳定酶，含有酶的组合物及其使用方法。

3. 发明申请

WO2010018989A2 LIGHTWEIGHT BODY FOR A HOLLOW CONCRETE SLAB, AND UNIT PANEL FOR A HOLLOW CONCRETE SLAB USING SAME 审中-公开
标题翻译：用于空心混凝土板的轻体和用于空心混凝土板的单体板使用相同
公开(公告)号：WO2010018989A2
公开(公告)日：2010-02-18
申请号：PCT/KR2009004493
申请日：2009-08-12
申请人： TBS KOREA CO LTD , TVS FORUM CO LTD , KIM TAE-WAN , YUN SUNG-HO , KIM SANG-MO , YOON HYUNG-KEUN
发明人： KIM TAE-WAN , YUN SUNG-HO , KIM SANG-MO , YOON HYUNG-KEUN
IPC分类号： E04B5/32 , E04B5/16 , E04B5/43
CPC分类号： E04B5/36 , E04B5/328
摘要： The present invention relates to a unit panel for a hollow concrete slab integrally assembled with a lightweight body. The unit panel for a hollow concrete slab includes a lower wire mesh, a plurality of lightweight bodies disposed on the lower wire mesh, an upper wire mesh disposed on the lightweight bodies, and a truss member fixed to the upper wire mesh and the lower wire mesh. The lower wire mesh, the lightweight bodies, the upper wire mesh, and the truss member are assembled in advance in a factory. Each of the lightweight bodies includes a semispherical upper lightweight body, a semispherical lower lightweight body facing the upper lightweight body, and a cylindrical height adjusting portion interposed between the upper lightweight body and the lower lightweight body. The upper and the lower lightweight bodies further have a plurality of grooves and double grooves. Whereby, the cost and time required for the arrangement and assembly of the lightweight bodies in the field can be reduced to shorten the overall construction period, minimize defects in the field, and reduce costs. The present invention can be applied even in the case of a varying thickness of the slab, thereby reducing costs. The present invention has grooves for the easy fixation of reinforcing rods or wire meshes for preventing the buoyancy of the lightweight bodies, and reduces costs by reducing concrete consumption. Further, the lightweight body of the present invention has an increased volume to reduce the consumption of concrete, and the height adjusting portion of the present invention adjusts the height of the lightweight body even when the lightweight body has a large volume, costs can be reduced as the present invention can be applied in the case of a varying thickness of the slab without the need for manufacturing lightweight bodies in a variety of sizes.
摘要翻译：用于空心混凝土板的单元板本发明涉及一种与轻质体一体组装的空心混凝土板单元板。用于空心混凝土板的单元板包括下金属丝网，设置在下金属丝网上的多个轻质体，设置在轻质体上的上金属丝网，以及固定到上金属丝网和下金属丝网上的桁架构件目。下部金属丝网，轻量物体，上部金属丝网和桁架部件预先在工厂组装。每个轻量化本体包括半球形的上部轻量级本体，面向上部轻量级本体的半球形下部轻量级本体以及设置在上部轻量级本体和下部轻量级本体之间的圆柱形高度调节部分。上部和下部轻质体还具有多个凹槽和双凹槽。由此，可以减少轻质物体在现场布置和组装所需的成本和时间，以缩短整个施工周期，最小化现场缺陷并降低成本。即使在厚度变化的情况下也可以应用本发明，从而降低成本。本发明具有用于容易固定用于防止轻量物体的浮力的增强杆或金属丝网的凹槽，并且通过减少混凝土消耗来降低成本。此外，本发明的轻量化体的体积增大，能够减少混凝土的消耗量，即使在轻量化体的体积大的情况下，本发明的高度调整部也能够调整轻量化体的高度，能够降低成本因为本发明可应用于板坯厚度变化的情况，而不需要制造各种尺寸的轻质体。

4. 发明申请

WO2006019685A2 COMPOUNDS AND THEIR PREPARATION FOR THE TREATMENT OF ALZHEIMER'S DISEASE BY INHIBITING BETA-AMYLOID PEPTIDE PRODUCTION 审中-公开
标题翻译：通过抑制β-淀粉样蛋白肽生产来治疗阿尔茨海默病的化合物及其制备方法
公开(公告)号：WO2006019685A2
公开(公告)日：2006-02-23
申请号：PCT/US2005024533
申请日：2005-07-11
申请人： UNIV COLUMBIA , LANDRY DONALD W , DENG SHIXIAN , KIM TAE-WAN , PARK JEONG HILL
发明人： LANDRY DONALD W , DENG SHIXIAN , KIM TAE-WAN , PARK JEONG HILL
IPC分类号： C07J17/00 , A61K31/704
CPC分类号： C07J17/00
摘要： The present invention provides novel ginsenoside compounds, compositions (e.g. pharmaceutical compositions) comprising the ginsenoside compounds, and methods for the synthesis of these ginsenoside compounds. Additionally, the present invention provides methods for inhibiting beta-amyloid peptide production and methods for treating or preventing a pathological condition, particularly, neurodegeneration diseases (e.g. Alzheimer's disease), using these ginsenoside compounds.
摘要翻译：本发明提供了新型人参皂苷化合物，包含人参皂苷化合物的组合物（例如药物组合物），以及合成这些人参皂苷化合物的方法。此外，本发明提供了用于抑制β-淀粉样肽产生的方法以及使用这些人参皂苷化合物治疗或预防病理状态，特别是神经变性疾病（例如阿尔茨海默氏病）的方法。

5. 发明申请

WO2012122405A3 SCREENING ASSAYS USING STEM CELLS AND STEM CELL-DERIVED NEURONS FROM MOUSE MODELS OF ALZHEIMER'S DISEASE 审中-公开
标题翻译：使用干细胞和干细胞衍生的神经元从阿尔茨海默病的小鼠模型进行筛选测定
公开(公告)号：WO2012122405A3
公开(公告)日：2014-04-17
申请号：PCT/US2012028345
申请日：2012-03-08
申请人： UNIV COLUMBIA , KIM TAE-WAN , MCINTIRE LAURA BETH JOHNSON , LANDMAN NATALIE , FINAN GINA
发明人： KIM TAE-WAN , MCINTIRE LAURA BETH JOHNSON , LANDMAN NATALIE , FINAN GINA
IPC分类号： C12N15/09
CPC分类号： G01N33/56966 , A61K31/01 , A61K31/03 , A61K31/085 , A61K31/137 , A61K31/145 , A61K31/15 , A61K31/41 , A61K31/473 , A61K31/5375 , A61K31/7048 , C12N5/0619 , C12N2501/385 , C12N2506/02 , C12N2533/50 , C12N2533/52 , G01N33/5058 , G01N2800/2821
摘要： Successful CNS drug discovery requires a scalable, highly physiological neuronal model. Using directed differentiation of mouse embryonic stem (mES) cells, including mES cells isolated from a mouse model of Alzheimer's disease (AD), a highly homogeneous primary neuronal model amenable to phenotypic assays for production and synaptotoxicity of amyloid &bgr;-peptide was developed. This model furnishes a highly physiological and AD-relevant platform suitable for high throughput small molecule and functional genetic screens, providing specific small molecule compounds identified by such screens.
摘要翻译：成功的CNS药物发现需要可扩展的，高度生理的神经元模型。使用小鼠胚胎干细胞（mES）细胞的定向分化，包括从阿尔茨海默氏病（AD）的小鼠模型分离的mES细胞，开发了适用于淀粉样蛋白和生物肽的生产表型测定和突触毒性的高度均一的原代神经元模型。该模型提供高生理和AD相关平台，适用于高通量小分子和功能遗传筛选，提供通过这种筛选鉴定的特异性小分子化合物。

6. 发明申请

WO2008064244A3 PHOSPHOINOSITIDE MODULATION FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES 审中-公开
标题翻译：磷酸肌醇调节治疗神经退行性疾病
公开(公告)号：WO2008064244A3
公开(公告)日：2008-12-18
申请号：PCT/US2007085274
申请日：2007-11-20
申请人： UNIV COLUMBIA , KIM TAE-WAN , DIPAOLO GILBERT , KANG MIN SUK , BERMAN DIEGO , MCINTIRE LAURA BETH JOHNSON
发明人： KIM TAE-WAN , DIPAOLO GILBERT , KANG MIN SUK , BERMAN DIEGO , MCINTIRE LAURA BETH JOHNSON
IPC分类号： A61P25/28
CPC分类号： A61K31/663
摘要： The present invention relates to the use of agents that inhibit the toxic effects of amyloid oligomers by increasing intracellular levels of phosphoinositol 4- phosphate (PI(4)P, or "PIP") and/or phosphotidylinositol 4,5-biphosphate (PI(4,5)P2 or "PIP2"), the use of such agents for the treatment of neurodegenerative diseases, methods of treating neurodegenerative diseases by administration of agents which alter lipid metabolism, and methods of identifying agents which alter the association of presenilins with ?-secretase and lipid rafts.
摘要翻译：本发明涉及通过增加细胞内磷酸肌醇4-磷酸（PI（4）P或“PIP”）和/或磷脂酰肌醇4,5-二磷酸（PI（4）P）的抑制淀粉样蛋白低聚物毒性作用的试剂的用途， 4,5）P2或“PIP2”），这些药剂用于治疗神经退行性疾病的用途，通过施用改变脂质代谢的药剂治疗神经变性疾病的方法，以及鉴定改变早老素与β 分泌酶和脂筏。

7. 发明申请

WO2006118630A3 PHOSPHOINOSITIDE MODULATION FOR THE TREATMENT OF ALZHEIMER'S DISEASE 审中-公开
标题翻译：用于治疗阿尔茨海默病的磷酸盐调节剂
公开(公告)号：WO2006118630A3
公开(公告)日：2007-11-15
申请号：PCT/US2006005745
申请日：2006-02-17
申请人： UNIV COLUMBIA , KIM TAE-WAN , LANDMAN NATALIE
发明人： KIM TAE-WAN , LANDMAN NATALIE
IPC分类号： A01N57/26 , A61K31/685
CPC分类号： A61K31/5377 , A61K31/661 , A61K31/683
摘要： The present invention relates to methods of treating Alzheimer's Disease which utilize agents that increase neuronal phosphotidylinositol 4,5- biphosphate (PIP2), and to differentiated stem cell-based assay systems that may be used to identify agents that modulate phosphoinositide levels and thereby treat a variety of diseases. It is based, at least in part, on the discovery that edelfosine, an agent that increases PIP2 levels by inhibiting an enzyme that catalyzes PIP2 breakdown, decreases levels of neurotoxic Aß42 peptide, particularly in cells expressing a mutant presenilin gene associated with Familial Alzheimer' s Disease.
摘要翻译：本发明涉及治疗阿尔茨海默氏病的方法，该方法利用增加神经元磷脂酰肌醇4,5-二磷酸（PIP2）的药物，以及可用于鉴定调节磷酸肌醇水平的药物的分化的基于干细胞的测定系统，从而治疗多种疾病至少部分地基于以下发现：通过抑制催化PIP2分解的酶来增加PIP2水平的药物降低神经毒性Aβ42肽的水平，特别是在表达与家族性阿尔茨海默病相关的突变型早老蛋白基因的细胞中，的疾病

8. 发明申请

WO2005044196A2 NOVEL MODULATORS OF AMYLOID-BETA PRODUCTION AND USES THEREOF 审中-公开
标题翻译： AMYLOID-BETA生产的新型调节剂及其用途
公开(公告)号：WO2005044196A2
公开(公告)日：2005-05-19
申请号：PCT/US2004036459
申请日：2004-11-01
申请人： UNIV COLUMBIA , KIM TAE-WAN , LEE HAHN-JUN
发明人： KIM TAE-WAN , LEE HAHN-JUN
IPC分类号： A61K38/00 , C07H21/04 , C07K14/47 , C12Q1/68 , A61K
CPC分类号： C07H21/04 , A61K38/00 , C07K14/4702 , C12Q1/6883
摘要： The present invention provides isolated nucleic acid sequences encoding presenilin stabilization factor (PSF) and PSF-like (PSFL) protein, vectors comprising same, host cells transformed with the vectors, and transgenic animals containing the host cells. The present invention further provides purified PSF and PSFL polypeptides, methods for making same, and pharmaceutical compositions comprising the polypeptides. Also provided are agents reactive with the nucleic acid sequences and polypeptides, kits comprising same, and methods for producing same. The present invention further provides methods for decreasing amyloid-beta (Aß) production, destabilizing presenilin or nicastrin, destabilizing a gamma-secretase complex, and inhibiting activity of gamma-secretase, and pharmaceutical compositions for accomplishing same. The present invention further provides methods for treating neurodegeneration in a subject. Finally, the present invention provides an in vitro system for identifying an agent that modulates production of Aß or an Aß precursor, methods for making and using same, and agents identified by same.
摘要翻译：本发明提供编码早老蛋白稳定因子（PSF）和PSF样（PSFL）蛋白的分离的核酸序列，包含其的载体，用载体转化的宿主细胞和含有宿主细胞的转基因动物。本发明还提供了纯化的PSF和PSFL多肽，其制备方法以及包含多肽的药物组合物。还提供了与核酸序列和多肽反应的试剂，包含其的试剂盒及其制备方法。本发明还提供降低淀粉样蛋白β（Aß）产生，去稳定早老蛋白或奈米卡品，去稳定γ-分泌酶复合物和抑制γ-分泌酶活性的方法和用于实现γ-分泌酶的药物组合物的方法。本发明还提供了治疗受试者神经变性的方法。最后，本发明提供了用于鉴定调节Aβ或Aβ前体的生产的试剂的体外系统，用于制备和使用它们的方法以及由其鉴定的试剂。

9. 发明申请

WO2008070439A3 NOVEL BACE1 INTERACTING PROTEINS AND USES THEREOF 审中-公开
标题翻译：新型BACE1相互作用蛋白及其用途
公开(公告)号：WO2008070439A3
公开(公告)日：2008-12-18
申请号：PCT/US2007085115
申请日：2007-11-19
申请人： UNIV COLUMBIA , KIM TAE-WAN , OKADA HIROKAZU
发明人： KIM TAE-WAN , OKADA HIROKAZU
IPC分类号： A61K31/70 , C12Q1/68 , G01N33/53
CPC分类号： G01N33/6896 , G01N2333/4703 , G01N2333/4709 , G01N2500/02 , G01N2800/2814
摘要： The present invention relates to the identification of a number of proteins which interact with ß-site Amyloid precursor protein Cleaving Enzyme-1 ("BACE1"), an enzyme involved in the generation of amyloid ß-peptide, the major component of Alzheimer's Disease-associated amyloid plaques. The BACE1 interacting proteins identified by the invention may be used as novel targets in the treatment of Alzheimer's Disease and other amyloid-ß-related disorders.
摘要翻译：本发明涉及许多与β位淀粉状蛋白前体蛋白相互作用的蛋白的鉴定，切割酶-1（“BACE1”），参与产生淀粉状蛋白β肽的酶，阿尔茨海默病的主要成分 - 相关的淀粉样斑块。本发明鉴定的BACE1相互作用蛋白可以用作治疗阿尔茨海默病和其他淀粉状蛋白β相关病症的新靶点。

10. 发明申请

WO2006124012A3 COMPOUNDS FOR TREATING ALZHEIMER'S DISEASE AND FOR INHIBITING BETA-AMYLOID PEPTIDE PRODUCTION 审中-公开
标题翻译：用于治疗阿尔茨海默病和抑制β-淀粉样肽生产的化合物
公开(公告)号：WO2006124012A3
公开(公告)日：2007-08-23
申请号：PCT/US2005014659
申请日：2005-04-28
申请人： UNIV COLUMBIA , KIM TAE-WAN , CHUNG SUNGKWON
发明人： KIM TAE-WAN , CHUNG SUNGKWON
IPC分类号： C07J9/00 , A61K31/56 , A61K31/57 , A61K31/704 , C07H15/24 , C07J17/00
CPC分类号： C07J17/00 , C07H15/24
摘要： The present invention provides compositions and methods for treating and preventing Alzheimer's disease by administering to a subject an effective amount of a dammarane or ginsenoside compound. The invention also provides compositions and methods for modulating beta-amyloid protein production, including Aß42 in a cell. The invention further provides compositions and methods for treating and preventing neurodegeneration by administering to a subject an effective amount of a dammarane or ginsenoside compound. Additionally, the invention provides kits for use in treating and/or preventing Alzheimer's disease and neurodegeneration, as well as for reducing the production of beta-amyloid protein.
摘要翻译：本发明提供了通过向受试者施用有效量的dammarane或人参皂苷化合物来治疗和预防阿尔茨海默氏病的组合物和方法。本发明还提供用于调节β-淀粉样蛋白产生的组合物和方法，包括细胞中的Aβ42。本发明还提供了通过向受试者施用有效量的dammarane或人参皂苷化合物来治疗和预防神经变性的组合物和方法。另外，本发明提供了用于治疗和/或预防阿尔茨海默氏病和神经变性的试剂盒，以及用于降低β-淀粉样蛋白质的产生。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式